[go: up one dir, main page]

EA201890042A1 - Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) - Google Patents

Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)

Info

Publication number
EA201890042A1
EA201890042A1 EA201890042A EA201890042A EA201890042A1 EA 201890042 A1 EA201890042 A1 EA 201890042A1 EA 201890042 A EA201890042 A EA 201890042A EA 201890042 A EA201890042 A EA 201890042A EA 201890042 A1 EA201890042 A1 EA 201890042A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
mva
relates
vaccine against
ankara
Prior art date
Application number
EA201890042A
Other languages
English (en)
Inventor
Робин Штайгервальд
Маркус Калла
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of EA201890042A1 publication Critical patent/EA201890042A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к модифицированным поксвирусным векторам и к способам их получения и применения. В частности, изобретение относится к вакцине против инфекции ВЯ на основе рекомбинантного модифицированного вируса осповакцины Анкара (на основе MVA) и связанным продуктам, способам и применению. Конкретно, настоящее изобретение относится к генномодифицированным (рекомбинантным) векторам MVA, содержащим по меньшей мере одну гетерологичную нуклеотидную последовательность, которая кодирует антигенную детерминанту белка ВЯ. Кроме того, изобретение относится к продуктам, способам и их применению, например, подходящим для индукции у пациента защитного иммунного ответа.
EA201890042A 2015-06-15 2016-06-15 Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) EA201890042A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175738P 2015-06-15 2015-06-15
PCT/EP2016/063691 WO2016202828A1 (en) 2015-06-15 2016-06-15 Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine

Publications (1)

Publication Number Publication Date
EA201890042A1 true EA201890042A1 (ru) 2018-05-31

Family

ID=56321898

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890042A EA201890042A1 (ru) 2015-06-15 2016-06-15 Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)

Country Status (11)

Country Link
US (2) US11103570B2 (ru)
EP (1) EP3307309A1 (ru)
CN (1) CN107709554A (ru)
AU (2) AU2016278806A1 (ru)
BR (1) BR112017026649A2 (ru)
CA (1) CA2987159A1 (ru)
CL (1) CL2017003224A1 (ru)
EA (1) EA201890042A1 (ru)
MX (1) MX2017016273A (ru)
WO (1) WO2016202828A1 (ru)
ZA (1) ZA201707985B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890042A1 (ru) * 2015-06-15 2018-05-31 Бавариан Нордик А/С Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US12150988B2 (en) 2018-09-06 2024-11-26 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
CN111926043A (zh) * 2020-08-10 2020-11-13 中国农业科学院兰州兽医研究所 共表达fmdv和pprv抗原基因重组病毒的构建方法
GB202217045D0 (en) * 2022-11-15 2022-12-28 Univ Cape Town Recombinant lsdv vectored foot and mouth disease antigenic constructs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0115533B8 (pt) 2000-11-23 2021-05-25 Bavarian Nordic As variação do vírus vaccinia ankara modificado
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
IL164177A0 (en) * 2002-05-16 2005-12-18 Bavarian Nordic As Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
EP1773387B1 (en) * 2004-06-25 2013-06-12 Merial Ltd. Avipox recombinants expressing foot and mouth disease virus genes
JP2012509678A (ja) * 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ 組換えウイルス発現のためのプロモーター
GB0918375D0 (en) * 2009-10-20 2009-12-02 Animal Health Inst Construct
ES2617743T3 (es) * 2010-03-12 2017-06-19 Merial, Inc. Vacunas recombinantes del virus de la lengua azul y sus utilizaciones
EA201890042A1 (ru) * 2015-06-15 2018-05-31 Бавариан Нордик А/С Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
US10385319B2 (en) * 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof

Also Published As

Publication number Publication date
US20180185466A1 (en) 2018-07-05
BR112017026649A2 (pt) 2018-08-28
EP3307309A1 (en) 2018-04-18
AU2022205166A1 (en) 2022-08-04
US20210393766A1 (en) 2021-12-23
CA2987159A1 (en) 2016-12-22
AU2016278806A1 (en) 2017-12-14
MX2017016273A (es) 2018-04-20
CN107709554A (zh) 2018-02-16
WO2016202828A1 (en) 2016-12-22
NZ737583A (en) 2025-02-28
ZA201707985B (en) 2024-04-24
US11103570B2 (en) 2021-08-31
CL2017003224A1 (es) 2018-04-20
AU2022205166B2 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
MX2017002791A (es) Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
CY1124254T1 (el) Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
EA201990718A1 (ru) Векторы аденовируса собачьих
EA202091516A1 (ru) Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA201892735A1 (ru) Состав вакцины против hiv
FI3656395T3 (fi) Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan
MX2020006471A (es) Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
EA201990711A1 (ru) Новый ehv сайт инсерции orf70
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
EA201990719A1 (ru) Новые промоторы
MX2019007924A (es) Vacunas contra la influenza.
EA202092164A1 (ru) Новый ehv с инактивированным ul18 и/или ul8
EA202193150A2 (ru) Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
EP3939991A4 (en) NOVEL RECOMBINANT INFLUENZA VIRUS EDUCATING IMMUNE AND THERAPEUTIC RESPONSES AGAINST HETEROLOGOUS INFLUENZA VIRUS, AND GENETIC VACCINE AND THERAPEUTIC VACCINE COMPRISING THEM
EA202191862A3 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
BR112019003181A2 (pt) composição para aumentar uma resposta imune em animal, método para induzir uma resposta imune protetora em um sujeito, e, uso da composição na preparação de um medicamento.
AR105134A1 (es) Vacunas contra la influenza con coincidencia antigénica